Chemotherapy resistance and relapses are common in high-risk neuroblastoma (NB). Here,
we developed a clinically relevant in vivo treatment protocol mimicking the first-line five-…

Patient-derived xenografts (PDX) and the Avatar, a single PDX mirroring an individual
patient, are emerging tools in preclinical cancer research. However, the consequences of …

The PI 3K pathway is a major driver of cancer progression. However, clinical resistance to
PI 3K inhibition is common. IBL ‐302 is a novel highly specific triple PIM , PI 3K, and mTOR …

The bone marrow microenvironment provides indispensable factors to sustain blood production
throughout life. It is also a hotspot for the progression of hematologic disorders and the …

Wilms tumour is a paediatric malignancy with features of halted kidney development. Here,
we demonstrate that the Iroquois homeobox genes IRX3 and IRX5 are essential for …

High-risk neuroblastoma has a poor prognosis despite intense treatment, demonstrating the
need for new therapeutic strategies. Here we evaluated the effects of rigosertib (ON-01910.…

Neuroblastoma (NB) is a pediatric cancer of the sympathetic nervous system that accounts
for 15% of childhood cancer deaths. High-risk (HR) NB tumors are treated with an aggressive …

Neuroblastoma is a pediatric tumor originating from the developing sympathetic nervous
system, most often arising in the adrenal medulla in children below 5 years of age. After …

e21503 Background: Neuroblastoma (NB) is a solid pediatric tumor that causes 15% of
childhood cancer deaths. High-risk patients have 50 to 70% mortality after 5 years. Currently, the …

Neuroblastoma is an embryonic tumor of the sympathetic nervous system which accounts
for 15% of childhood cancer-related deaths. It is characterized by a wide spectrum of clinical …